123 related articles for article (PubMed ID: 746249)
1. Prognostic factors and treatment of multiple myeloma: interest of a cyclic sequential chemohormonotherapy combining cyclophosphamide, melphalan, and prednisone.
Belpomme D; Simon F; Pouillart P; Amor B; Feuilhade de Chauvin F; Belpomme A; Menkes C; Delrieu A; Depierre R; Le Mevel B; Serrou B; Fries D; Delbarre F; Mathé G
Recent Results Cancer Res; 1978; 65():28-40. PubMed ID: 746249
[TBL] [Abstract][Full Text] [Related]
2. The chemotherapy of plasma-cell myeloma and the incidence of acute leukemia.
Bergsagel DE; Bailey AJ; Langley GR; MacDonald RN; White DF; Miller AB
N Engl J Med; 1979 Oct; 301(14):743-8. PubMed ID: 481481
[TBL] [Abstract][Full Text] [Related]
3. A randomized trial of melphalan and prednisone versus melphalan, prednisone, cyclophosphamide, MeCCNU, and vincristine in untreated multiple myeloma.
Pavlovsky S; Saslavsky J; Tezanos Pinto M; Palmer L; Curuchet M; Lein JM; Garay G; Dragosky M; Quiroga-Micheo E; Huberman AB
J Clin Oncol; 1984 Jul; 2(7):836-40. PubMed ID: 6376722
[TBL] [Abstract][Full Text] [Related]
4. Cross-resistance to alkylating agents in multiple myeloma.
Bladé J; Feliú E; Rozman C; Estapé J; Millá A; Montserrat E
Cancer; 1983 Sep; 52(5):786-9. PubMed ID: 6871821
[TBL] [Abstract][Full Text] [Related]
5. Comparison of two combination chemotherapy regimens for multiple myeloma: methyl-CCNU, cyclophosphamide, and prednisone versus melphalan and prednisone.
Cavagnaro F; Lein JM; Pavlovsky S; Becherini JO; Pileggi JE; Micheo EQ; Jait C; Musso A; Suárez A; Pizzolato M
Cancer Treat Rep; 1980 Jan; 64(1):73-9. PubMed ID: 6991106
[TBL] [Abstract][Full Text] [Related]
6. Natural interferon-alpha in combination with melphalan/prednisone versus melphalan/prednisone in the treatment of multiple myeloma stages II and III: a randomized study from the Myeloma Group of Central Sweden.
Osterborg A; Björkholm M; Björeman M; Brenning G; Carlson K; Celsing F; Gahrton G; Grimfors G; Gyllenhammar H; Hast R
Blood; 1993 Mar; 81(6):1428-34. PubMed ID: 8453092
[TBL] [Abstract][Full Text] [Related]
7. [Analysis of the results of treatment of multiple myeloma].
Snigurowicz J; Rostkowska J; Kraj M; Mariańska B
Acta Haematol Pol; 1979 Oct; 10(4):227-35. PubMed ID: 539350
[TBL] [Abstract][Full Text] [Related]
8. Comparison of melphalan and prednisone with vincristine, carmustine, melphalan, cyclophosphamide, and prednisone in the treatment of multiple myeloma: results of Eastern Cooperative Oncology Group Study E2479.
Oken MM; Harrington DP; Abramson N; Kyle RA; Knospe W; Glick JH
Cancer; 1997 Apr; 79(8):1561-7. PubMed ID: 9118039
[TBL] [Abstract][Full Text] [Related]
9. The addition of interferon or high dose cyclophosphamide to standard chemotherapy in the treatment of patients with multiple myeloma: phase III Eastern Cooperative Oncology Group Clinical Trial EST 9486.
Oken MM; Leong T; Lenhard RE; Greipp PR; Kay NE; Van Ness B; Keimowitz RM; Kyle RA
Cancer; 1999 Sep; 86(6):957-68. PubMed ID: 10491521
[TBL] [Abstract][Full Text] [Related]
10. Weekly cyclophosphamide and alternate-day prednisone: an effective secondary therapy in multiple myeloma.
Wilson K; Shelley W; Belch A; Brandes L; Bergsagel D; Klimo P; White D; Willan A
Cancer Treat Rep; 1987 Oct; 71(10):981-2. PubMed ID: 3652060
[TBL] [Abstract][Full Text] [Related]
11. Phase III study of intermittent carmustine (BCNU), cyclophosphamide, and prednisone versus intermittent melphalan and prednisone in myeloma.
Abramson N; Lurie P; Mietlowski WL; Schilling A; Bennett JM; Horton J
Cancer Treat Rep; 1982 Jun; 66(6):1273-7. PubMed ID: 7044535
[TBL] [Abstract][Full Text] [Related]
12. Multiple myeloma: VMCP/VBAP alternating combination chemotherapy is not superior to melphalan and prednisone even in high-risk patients.
Boccadoro M; Marmont F; Tribalto M; Avvisati G; Andriani A; Barbui T; Cantonetti M; Carotenuto M; Comotti B; Dammacco F
J Clin Oncol; 1991 Mar; 9(3):444-8. PubMed ID: 1999714
[TBL] [Abstract][Full Text] [Related]
13. Intermittent high-dose melphalan/prednisone vs continuous low-dose melphalan treatment in multiple myeloma.
Ahre A; Björkholm M; Mellstedt H; Holm G; Brenning G; Engstedt L; Gahrton G; Hällen J; Johansson B; Johansson SG; Karnström L; Killander A; Lerner R; Lockner D; Lönnqvist B; Simonsson B; Stalfelt AM; Ternstedt B; Wadman B
Eur J Cancer Clin Oncol; 1983 Apr; 19(4):499-506. PubMed ID: 6345174
[TBL] [Abstract][Full Text] [Related]
14. [Multiple myeloma with high tumoral mass. Treatment combining melphalan, cyclophosphamide, vincristine, CCNU and prednisone. 35 cases].
Brun B; Kuentz M; Man NG; Feuilhade F; Bierling P; Vernant JP; Farcet JP; Cordonnier C; Reyes F; Dreyfus B; Rochant H
Presse Med; 1983 Apr; 12(19):1205-10. PubMed ID: 6221296
[TBL] [Abstract][Full Text] [Related]
15. Treatment of multiple myeloma with an intensive 5-drug combination or intermittent melphalan and prednisone; a randomised multicentre trial. Finnish Leukaemia Group.
Palva IP; Ahrenberg P; Ala-Harja K; Almqvist A; Apajalahti J; Hallman H; Hänninen A; Ilvonen M; Isomaa B; Järvenpää E
Eur J Haematol; 1987 Jan; 38(1):50-4. PubMed ID: 3582605
[TBL] [Abstract][Full Text] [Related]
16. Effectiveness of two-stage treatment of multiple myeloma with melphalan and with melphalan in combination with cyclophosphamide, carmustine, vincristine and prednisone.
Snigurowicz J; Kraj M; Rostkowska J; Maj S; Mariańska B; Mendek E; Roszkowski S; Kilian Z; Kołakowski L
Arch Immunol Ther Exp (Warsz); 1981; 29(2):145-53. PubMed ID: 7030265
[No Abstract] [Full Text] [Related]
17. Plasma cell myeloma: response of melphalan-resistant patients to high-dose intermittent cyclophosphamide.
Bergsagel DE; Cowan DH; Hasselback R
Can Med Assoc J; 1972 Nov; 107(9):851-5. PubMed ID: 4653931
[TBL] [Abstract][Full Text] [Related]
18. [Treatment of multiple myeloma in stages II and III with melphalan, prednisone, cyclophosphamide, vincristine and BCNU (M-2 protocol)].
Montalbán C; Sevilla F; Zapatero A; Blanco L; Sabán J; Serrano M; Serrano Ríos M
Rev Clin Esp; 1985 May; 176(8):392-5. PubMed ID: 3839590
[No Abstract] [Full Text] [Related]
19. Weekly low-dose cyclophosphamide and alternate-day prednisone: an effective low toxicity regimen for advanced myeloma.
Brandes LJ; Israels LG
Eur J Haematol; 1987 Oct; 39(4):362-8. PubMed ID: 3691759
[TBL] [Abstract][Full Text] [Related]
20. Alternating combination VCMP/VBAP chemotherapy versus melphalan/prednisone in the treatment of multiple myeloma: a randomized multicentric study of 487 patients.
Bladé J; San Miguel JF; Alcalá A; Maldonado J; Sanz MA; García-Conde J; Moro MJ; Alonso C; Besalduch J; Zubizarreta A
J Clin Oncol; 1993 Jun; 11(6):1165-71. PubMed ID: 8501503
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
